The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan.
Monday's start of Washington's 105-day legislative session also marked a new beginning for several Spokane-area lawmakers. The day included much of the pomp and circumstance one would expect, with ...